Treatment Preferences for Novel Type 2 Diabetes Oral Medications: Insights from the Asian Diabetes Patient Preference Study
Asian patients with T2DM preferred medication profile resembling SGLT2Is over DPP4Is. Understanding patient preferences may aid optimal glycemic control while reducing cardiovascular and renal risks.
Authors
- Mangesh Tiwaskar (ORCID: https://orcid.org/0000-0003-4024-0095)
- Chii‐Min Hwu (ORCID: https://orcid.org/0000-0002-8209-9627)
- Apeksha Bhandary (ORCID: https://orcid.org/0000-0001-7660-8694)
- I‐Jy Chang (ORCID: https://orcid.org/0000-0001-5565-8174)
- Mintaek Lim
Institutions
- University of Santo Tomas Hospital (PH)
- Taipei Veterans General Hospital (TW)
- Shilpa (India) (IN)
- AstraZeneca (India) (IN)
Publication Details
- Journal
- Diabetes Therapy
- Published
- 2025-07-21
- DOI
- https://doi.org/10.1007/s13300-025-01770-3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Novo Nordisk
- Chang Gung Medical Foundation